Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aletris N Oligoplex is a homeopathic combination drug developed by Madaus (a subsidiary of Viatris) for the treatment and relief of symptoms associated with uterine prolapse (Gebärmuttersenkung) and other disorders of the female reproductive organs. It is formulated as an oral liquid mixture (drops) or as a liquid dilution for injection (intravenous, intramuscular, or subcutaneous administration). The preparation contains a combination of four active homeopathic ingredients: *Aletris farinosa* (unicorn root), *Chamaelirium luteum* (blazing star, also known as *Helonias dioica*), *Lilium lancifolium* (tiger lily, also known as *Lilium tigrinum*), and *Pulsatilla pratensis* (pasque flower). As a homeopathic remedy, its mechanism of action is based on the principles of homeopathy, utilizing highly diluted natural extracts to stimulate the body's self-healing processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aletris N Oligoplex.